162 related articles for article (PubMed ID: 30502232)
21. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
Neukam K; Morano-Amado LE; Rivero-Juárez A; Mancebo M; Granados R; Téllez F; Collado A; Ríos MJ; de Los Santos-Gil I; Reus-Bañuls S; Vera-Méndez F; Geijo-Martínez P; Montero-Alonso M; Suárez-Santamaría M; Pineda JA
HIV Clin Trials; 2017 May; 18(3):126-134. PubMed ID: 28599618
[TBL] [Abstract][Full Text] [Related]
22. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
Pineda JA; Morano-Amado LE; Granados R; Macías J; Téllez F; García-Deltoro M; Ríos MJ; Collado A; Delgado-Fernández M; Suárez-Santamaría M; Serrano M; Miralles-Álvarez C; Neukam K; ;
Clin Microbiol Infect; 2017 Jun; 23(6):409.e5-409.e8. PubMed ID: 28137633
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.
Zappulo E; Scotto R; Buonomo AR; Maraolo AE; Pinchera B; Gentile I
Expert Opin Pharmacother; 2020 Feb; 21(3):261-273. PubMed ID: 31914336
[No Abstract] [Full Text] [Related]
24. Hepatitis C Virus Infection and Treatment as Independent Prognostic Factors in Diffuse Large B-Cell Lymphoma Egyptian Patients.
Elbedewy TA; Elashtokhy HEA; Abd-Elsalam S; Suliman MA
Curr Cancer Drug Targets; 2020; 20(8):638-645. PubMed ID: 32392114
[TBL] [Abstract][Full Text] [Related]
25. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study.
Michot JM; Canioni D; Driss H; Alric L; Cacoub P; Suarez F; Sibon D; Thieblemont C; Dupuis J; Terrier B; Feray C; Tilly H; Pol S; Leblond V; Settegrana C; Rabiega P; Barthe Y; Hendel-Chavez H; Nguyen-Khac F; Merle-Béral H; Berger F; Molina T; Charlotte F; Carrat F; Davi F; Hermine O; Besson C;
Am J Hematol; 2015 Mar; 90(3):197-203. PubMed ID: 25417909
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma.
Tsutsumi Y; Nakayama C; Kamada K; Kikuchi R; Kudo D; Ito S; Matsuoka S; Shiratori S; Yamamoto Y; Naruse H; Teshima T
Ann Hematol; 2017 Dec; 96(12):2057-2061. PubMed ID: 28939993
[TBL] [Abstract][Full Text] [Related]
28. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.
Arcaini L; Besson C; Frigeni M; Fontaine H; Goldaniga M; Casato M; Visentini M; Torres HA; Loustaud-Ratti V; Peveling-Oberhag J; Fabris P; Rossotti R; Zaja F; Rigacci L; Rattotti S; Bruno R; Merli M; Dorival C; Alric L; Jaccard A; Pol S; Carrat F; Ferretti VV; Visco C; Hermine O
Blood; 2016 Nov; 128(21):2527-2532. PubMed ID: 27605512
[TBL] [Abstract][Full Text] [Related]
29. Most patients with HCV-associated lymphoma present with mild liver disease: a call to revise antiviral treatment prioritization.
Torres HA; Mahale P
Liver Int; 2015 Jun; 35(6):1661-4. PubMed ID: 25779000
[TBL] [Abstract][Full Text] [Related]
30. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
31. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
[TBL] [Abstract][Full Text] [Related]
32. HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents.
Carrier P; Jaccard A; Jacques J; Tabouret T; Debette-Gratien M; Abraham J; Mesturoux L; Marquet P; Alain S; Sautereau D; Essig M; Loustaud-Ratti V
Liver Int; 2015 Oct; 35(10):2222-7. PubMed ID: 26104059
[TBL] [Abstract][Full Text] [Related]
33. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
Mahale P; Engels EA; Li R; Torres HA; Hwang LY; Brown EL; Kramer JR
Gut; 2018 Mar; 67(3):553-561. PubMed ID: 28634198
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of histological dynamics, kidney function and diabetes in liver transplant patients after antiviral treatment with direct-acting antivirals: Therapy of HCV-recurrence.
Teegen EM; Dürr M; Maurer MM; Eurich F; Vollbort A; Globke B; Bahra M; Blaeker H; Pratschke J; Eurich D
Transpl Infect Dis; 2019 Feb; 21(1):e13020. PubMed ID: 30375710
[TBL] [Abstract][Full Text] [Related]
35. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
[TBL] [Abstract][Full Text] [Related]
36. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis.
Merchante N; Rivero-Juárez A; Téllez F; Merino D; Ríos-Villegas MJ; Villalobos M; Omar M; Rincón P; Rivero A; Pérez-Pérez M; Raffo M; López-Montesinos I; Palacios R; Gómez-Vidal MA; Macías J; Pineda JA;
J Antimicrob Chemother; 2018 Sep; 73(9):2435-2443. PubMed ID: 29982683
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma.
Pellicelli AM; Marignani M; Zoli V; Romano M; Morrone A; Nosotti L; Barbaro G; Picardi A; Gentilucci UV; Remotti D; D'Ambrosio C; Furlan C; Mecenate F; Mazzoni E; Majolino I; Villani R; Andreoli A; Barbarini G
World J Hepatol; 2011 Nov; 3(11):278-84. PubMed ID: 22125661
[TBL] [Abstract][Full Text] [Related]
38. Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
Dlouhy I; Torrente MÁ; Lens S; Rovira J; Magnano L; Giné E; Delgado J; Balagué O; Martínez A; Campo E; Forns X; Sánchez-Tapias JM; López-Guillermo A
Ann Hematol; 2017 Mar; 96(3):405-410. PubMed ID: 28035434
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients.
Hosry J; Miranda RN; Samaniego F; Economides MP; Torres HA
Int J Cancer; 2018 Mar; 142(5):940-948. PubMed ID: 29047108
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and safety of chronic hepatitis C treatment with direct-acting antivirals in patients with rheumatic diseases: A case-series.
Kida T; Umemura A; Kaneshita S; Sagawa R; Inoue T; Toyama S; Wada M; Kohno M; Oda R; Inaba T; Itoh Y; Kawahito Y
Mod Rheumatol; 2020 Nov; 30(6):1009-1015. PubMed ID: 31625432
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]